PolyPid (PYPD) Long-Term Investments (2019 - 2023)
PolyPid (PYPD) posted Long-Term Investments of $9.3 million for Q4 2023, down 20.99% sequentially from $11.8 million in Q4 2022, and down 20.99% YoY from $11.8 million in Q4 2022.
PolyPid (PYPD) Long-Term Investments (2019 - 2023) Analysis & Trends
PolyPid has reported Long-Term Investments for 5 years, with the latest figure at $9.3 million in Q4 2023.
- Quarterly Long-Term Investments fell 20.99% year-over-year to $9.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $9.3 million (down 20.99% YoY) and the FY2023 annual result came in at $9.3 million, down 20.99% from the prior year.
- Long-Term Investments slipped to $9.3 million in Q4 2023 per PYPD's latest filing, from $11.8 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $28.6 million in Q4 2020 and troughed at $6.4 million in Q4 2019.
- A 5-year average of $12.5 million and a median of $9.8 million in 2022 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2020 and 2021: Long-Term Investments jumped 351.06% in 2020, then plunged 67.1% in 2021.
- Over 5 years, Long-Term Investments stood at $6.4 million in 2019, then surged by 351.06% to $28.6 million in 2020, then slumped by 67.1% to $9.4 million in 2021, then climbed by 24.97% to $11.8 million in 2022, then slipped by 20.99% to $9.3 million in 2023.
- According to Business Quant data, Long-Term Investments over the past three periods registered $9.3 million, $11.8 million, and $9.8 million for Q4 2023, Q4 2022, and Q2 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - | 6.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 9.31 Mn |
| Dec 31, 2022 | 11.78 Mn |
| Jun 30, 2022 | 9.80 Mn |
| Dec 31, 2021 | 9.42 Mn |
| Jun 30, 2021 | 12.22 Mn |
| Dec 31, 2020 | 28.65 Mn |
| Dec 31, 2019 | 6.35 Mn |